Research Paper Volume 14, Issue 12 pp 5271—5291

Figure 7. Role of DMS in predicting efficacy of immunotherapy. (A) Kaplan-Meier curves displaying the survival difference of high and low DMS groups in IMvigor210 cohort. (B) The ratio of clinical response types in high DMS and low DMS groups in the IMvigor210 cohort when treated with anti-PD-1 immunotherapy. (C) Differences in DMS score between different clinical response types in the IMvigor210 cohort. (D) Survival analyses for DMS in TCGA-SKCM cohort. (E) The ratio of clinical response types in each group in the TCGA-SKCM cohort. (F, G) Differences in DMS score between different clinical response types in the TCGA-SKCM cohort. (H) Survival analyses for patients receiving anti-PD-L1 immunotherapy stratified by both neoantigen burden and DMS signature. (I) Differences in DMS score among different immune phenotypes. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. NEO, neoantigen burden.